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Abstract
Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids
may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis
has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests
that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and
prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and
mortality rates associated with prescription pain medications.
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Neuropathic pain (NP) is defined as pain caused by a
lesion or disease of the central or peripheral somatosen-
sory nervous system [1]. NP affects between 5% and 10%
of the US population [2] and examples include diabetic
neuropathy, complex regional pain syndrome, radiculo-
pathy, phantom limb pain, HIV sensory neuropathy, mul-
tiple sclerosis-related pain, and poststroke pain [3].
Neuropathic pain is difficult to treat and opioid analge-
sics are often prescribed [4]. Recent science has demon-
strated efficacy in treating NP with cannabis, [5-7] a safer
drug than opioids [8]. This paper suggests that physicians
who treat neuropathic pain should prescribe cannabis
prior to using opioids as a harm reduction (HR) strategy.
Topics covered include how harm reduction applies to
prescription opioid substitution, the legality of medicinal
cannabis, a comparison of cannabis to opioids, the
science on treating NP with cannabis and cannabinoids,
and the ethics of prescribing a drug which is deemed ille-
gal on the federal but not the state level.
Medicine relies upon the principle of, “First, do no
harm,” a n do n em i g h ts u p p l e m e n tt h ea x i o mt or e a d-
“First, do no harm, and second, reduce all the harm you
can.”“ Harm reduction” or “harm minimization” can be
defined in the broadest sense as strategies designed to
reduce risk or harm [9]. Those harmed may include the
individual, others impacted by the harmed person, and
society [9]. The substitution of a safer drug for one that
is more dangerous is considered harm reduction [10].
Specific examples of HR include prescribing methadone
or buprenorphine to replace heroin, [11] prescribing
nicotine patches to be used instead of smoking tobacco,
[12] and prescribing intranasal naloxone to patients on
o p i o i dt h e r a p yt ob eu t i l i z e di nc a s eo fo v e r d o s e[ 1 3 ] .
Substituting cannabis for prescribed opioids may be con-
sidered a harm reduction strategy.
Under the Federal Controlled Substance Act “mari-
huana” is illegal and classified as a schedule I substance-
meaning it has a high potential for abuse and no
accepted medical use [14]. However, sixteen states and
the District of Columbia have legalized cannabis for
medicinal use and these include Alaska, Arizona, Cali-
fornia, Colorado, Delaware, Hawaii, Maine, Michigan,
Montana, Nevada, New Jersey, New Mexico, Oregon,
Rhode Island, Vermont, and Washington [15]. Each
state law differs but all allow physicians to “authorize”
or “recommend” cannabis for specific ailments [16].
This “recommendation” affords legal protections for
patients to obtain and use medicinal cannabis, and may
be considered the “prescription.”
Cannabis (Cannabis sativa) and the opium poppy
(Papaver somniferum) are both ancient plants that have
been used medicinally for thousands of years [17,18].
The natural and synthetic derivatives of opium, includ-
ing morphine, are called “opioids.” [19] “Cannabinoids”
is the term for a class of compounds within cannabis of
which delta-9-tetrahydrocannabinol (THC) is the most
familiar [20]. Besides THC, approximately 100 other
cannabinoids have been identified [21,22] including one
of special scientific interest called “cannabidiol” (CBD)
[23]. The human body produces both endogenous can-
nabinoids (endocannabinoids) and opioids (endorphins)
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[24,25]. There is an extensive literature on opioids but
far less on cannabis/cannabinoids (CC).
Adverse effects from opioids include respiratory
depression, sedation, sleep disturbance, cognitive and
psychomotor impairment, delirium, hallucinations, sei-
zures, hyperalgesia, constipation, nausea, and vomiting
[26-28]. Adverse events from cannabis/cannabinoids
include psychotic episodes, anxiety or panic reactions,
memory impairment, reduced concentration, disorienta-
tion, lowered blood pressure and increased heart rate
[7,29-31]. In a systematic review Wang and colleagues
found most adverse events for short-term cannabis use
w e r en o ts e r i o u s ,a n dt h e r ew a sal a c ko fe v i d e n c et o
determine adverse effects for long-term use [32].
Opioids and cannabis share issues of addiction, physical
dependence, tolerance and withdrawal [5,33,34].
Between 1999 and 2006 approximately 65,000 people
died from opioid analgesic overdose [35]. Regarding fatal
overdose from cannabis, Carter and colleagues write, “...
this well documented fact: no one has ever died from an
overdose of cannabis.” [8] In addition, there is insufficient
data to demonstrate smoking cannabis causes lung can-
cer [36] but long-term use is associated with an increased
risk of respiratory problems [37]. Although, eating canna-
bis [38] avoids the respiratory issues. In 2001 the total
cost of prescription opioid abuse was estimated at $8.6
billion [39]. Unfortunately, there are no comprehensive
studies on the total cost of cannabis abuse. However,
enforcing the prohibition on cannabis costs an estimated
$7.7 billion per year [40]. Since the federal and most state
governments view any use of cannabis as abuse - includ-
ing medicinal use - one might include this cost. Accord-
ing to a report from the Substance Abuse and Mental
Health Services Administration between 1999 and 2009
admissions for treatment of nonheroin opioid abuse
increased approximately 516% while admissions for can-
nabis saw a 53% rise [41].
Nerve pain can be refractory to treatment [42] and
opioids are often used as a second-line therapy while
antidepressants and anticonvulsants are commonly used
first [4,43]. Moreover, opioids may provide only limited
pain relief and as Henry McQuay writes, “...you may be
able to decrease neuropathic pain with strong opioids,
b u tt h ed e c r e a s ei so f t e ns l i g h ta n di sa c h i e v e dw i t ha n
adverse eﬀect burden that will not be tolerable over
weeks to months.” [44] Cannabis and cannabinoid
research is in its relative infancy and many studies are
of short duration and with small sample sizes [6]. How-
ever, a number of review articles suggest that treating
neuropathic pain with cannabis/cannabinoids is effica-
cious and with moderate adverse effects [5-7]. The most
thorough of the systematic reviews was of randomized
controlled trials (RCTs) of CC therapy [6] which looked
at nine studies [45-53] whose focus was on treating dif-
ferent types of neuropathic pain with either smoked
cannabis, [45-48] a synthetic cannabinoid similar to
THC, [49,50] or a whole plant extract of THC and CBD
in a 1:1 ratio [51-53]. CBD may moderate the psychoac-
tive effect of THC and have analgesic properties [24].
Seven of the nine studies demonstrated efficacy for
using CC for neuropathic pain [45-49,52,53] while two
had mixed results, [50,51] and eight of the nine studies
found no serious adverse events [45-51,53].
A closer look at the four RCTs which evaluated
smoked cannabis for neuropathic pain [45-48] reveals
some common and contrasting elements (Table 1). Two
of the studies, Ware et al. [45] and Wilsey et al., [47]
examined cannabis in treating a variety of NP condi-
tions; while the other two, Ellis et al. [46] and Abrams
et al., [48] explored the effects of cannabis on HIV-
related neuropathic pain. Both Wilsey et al. [47] and
Abrams et al. [48] required participants to have pre-
viously used cannabis in order to reduce the risk of
adverse reactions from psychoactive effects. The RCTs
used cannabis with a variety of THC strengths ranging
from 0% for placebo [45-48] to 9.4% in Ware et al. [45]
Each study required participants to continue taking
their regular medications during the cannabis trials and
all found a significant decrease in pain compared to pla-
cebo [45-48]. In addition, adverse events were tolerable
for the vast majority of participants [45-48].
Commentators have suggested that patients should
use whole plant cannabis, as opposed to chemical deri-
vatives, because of other potentially beneficial com-
pounds [8,19]. In addition, a number of articles have
reported on interactions between cannabinoid and
opioid receptors which may result in enhanced analgesia
and a synergistic effect when CC is added to opioids
[54,55]. This may translate into patients being able to
reduce their opioid intake with adjuvant cannabinoid
therapy [5,29].
Although prescribing cannabis is legal in 16 states and
the District of Columbia, it remains illegal at the federal
level. Portions of the American Medical Association’s
Code of Medical Ethics, Opinion 1.02 - The Relation of
Law and Ethics reads, “Ethical values and legal princi-
ples are usually closely related, but ethical obligations
typically exceed legal duties. In some cases, the law
mandates unethical conduct.”“ In exceptional circum-
stances of unjust laws, ethical responsibilities should
supersede legal obligations.” [56] An “exceptional cir-
cumstance of unjust laws” may be interpreted as the
federal ban on cannabis for medical use. Sixteen states
and the District of Columbia found the federal govern-
ment’s prohibition on prescribing and using medicinal
cannabis so unjust as to create laws in direct violation
of federal statute. Therefore, one could surmise that
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is ethical even though it violates federal law. In addition,
Hayry suggests that the idea of “freedom” also provides
an ethical reason for prescribing cannabis and he writes,
“... whatever the legal situation, respect for the freedom
of the individual would imply that requests like this (for
medicinal cannabis) should be granted, either by health
professionals, or by society as a whole.” [57]
In states where medicinal cannabis is legal, physicians
who treat neuropathic pain with opioids should evaluate
their patients for a trial of cannabis and prescribe it
when appropriate prior to using opioids. There is suffi-
cient evidence of safety and efficacy for the use of CC in
the treatment of nerve pain relative to opioids and as
Carter et al write, “From a pharmacological prospective,
cannabinoids are considerably safer than opioids...” [8]
Prescribing cannabis in place of opioids for neuropathic
pain may reduce the morbidity and mortality rates asso-
ciated with prescription pain medications and may be
an effective harm reduction strategy.
[The subject of cannabis dosing is beyond the scope of
this paper but those interested should consider reading
Carter GT, Weydt P, Kyashna-Tocha M, Abrams DI.
Medicinal cannabis: rational guidelines for dosing.
IDrugs 2004;7:464-70.]
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have a more general analgesic
and anti-hyperalgesic effect.”
Study
Design
randomized, double-blind,
placebo-controlled, crossover
randomized, double-blind,
placebo-controlled, crossover
randomized, double-blind,
placebo-controlled, crossover
randomized, double-blind,
placebo-controlled
Sample
Size
21 38 28 50
Pain
Conditions
NP caused by trauma or
surgery, with allodynia or
hyperalgesia
spinal cord injury, peripheral NP,
and multiple-sclerosis
HIV infection, refractory NP HIV infection, HIV-SN
Exclusion
Criteria
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pregnant
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cannabis
active substance abuse, history
of psychosis or intolerance to
cannabinoids, serious medical
conditions
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Potency
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Length of
Study
4 phases over 8 weeks 3 sessions over ~ 4 weeks 5 study phases over 7 weeks 4 phases over 3 weeks
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greater compared to placebo.
Mood, physical disability, quality
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HIV-DSPN, HIV distal sensory polyneuropathy; HIV-SN, HIV-associated sensory neuropathy; NP, neuropathic pain; AE, adverse events
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